PDCD1 and gastric cancer: Although significant progress has been made in advanced GC, it should be noted that PD-1/PD-L1 inhibitors are not suitable for all patients with advanced GC, and immunobiological markers could screen suitable patients for PD-1/PD-L1 inhibitors.